Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer

Helen K. Chew, James H. Doroshow, Paul Frankel, Kim A. Margolin, George Somlo, Heinz Josef Lenz, Michael Gordon, Wu Zhang, Dongyun Yang, Christy Russell, Darcy Spicer, Tim Synold, Robert Bayer, Alexander Hantel, Patrick J. Stiff, Merry L. Tetef, David R. Gandara, Kathy S. Albain

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Purpose: Cisplatin and gemcitabine have single-agent activity in metastatic breast cancer, and preclinical data support synergy of the combination. Two parallel, phase II trials were conducted to evaluate the response rate, response duration, and toxicities of the combination. Genetic polymorphisms were analyzed for correlation with outcomes. Patients and Methods: Eligible women had measurable disease and heavily or minimally pretreated metastatic breast cancer. The heavily pretreated protocol required prior anthracycline and taxane therapy; cisplatin as part of high-dose therapy was allowed. All patients received cisplatin 25 mg/m2 on days 1 through 4 and gemcitabine 1,000 mg/m2 on days 2 and 8 of a 21-day cycle with prophylactic granulocyte colony-stimulating factor in the heavily pretreated group. Sera from a subset of patients were evaluated by polymerase chain reaction restriction fragment length polymorphism for polymorphisms in 10 genes of interest. Results: Of 136 women enrolled, 74 were heavily pretreated. Both protocols accrued to their two-stage design. The response rate for both the heavily and minimally pretreated cohorts was 26%, and the median durations of response were 5.3 and 5.9 months, respectively. In a multivariate analysis, hormone receptor-negative disease was associated with a higher response rate. The most common grades 3 or 4 toxicities were thrombocytopenia (71%), neutropenia (66%), and anemia (38%). In a subset of 55 patients, the xeroderma pigmentosum group D (XPD)-751, x-ray cross-complementing group 3 (XRCC3) and cytidine deaminase polymorphisms were significantly associated with clinical outcomes. Conclusion: Combination cisplatin and gemcitabine is active in metastatic breast cancer regardless of prior therapy. Genetic polymorphisms may tailor which patients benefit from this regimen.

Original languageEnglish (US)
Pages (from-to)2163-2169
Number of pages7
JournalJournal of Clinical Oncology
Volume27
Issue number13
DOIs
StatePublished - May 1 2009

Fingerprint

gemcitabine
Cisplatin
Breast Neoplasms
Genetic Polymorphisms
Cytidine Deaminase
Xeroderma Pigmentosum
Anthracyclines
Granulocyte Colony-Stimulating Factor
Neutropenia
Restriction Fragment Length Polymorphisms
Thrombocytopenia
Anemia
Therapeutics
Multivariate Analysis
X-Rays
Hormones
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. / Chew, Helen K.; Doroshow, James H.; Frankel, Paul; Margolin, Kim A.; Somlo, George; Lenz, Heinz Josef; Gordon, Michael; Zhang, Wu; Yang, Dongyun; Russell, Christy; Spicer, Darcy; Synold, Tim; Bayer, Robert; Hantel, Alexander; Stiff, Patrick J.; Tetef, Merry L.; Gandara, David R.; Albain, Kathy S.

In: Journal of Clinical Oncology, Vol. 27, No. 13, 01.05.2009, p. 2163-2169.

Research output: Contribution to journalArticle

Chew, HK, Doroshow, JH, Frankel, P, Margolin, KA, Somlo, G, Lenz, HJ, Gordon, M, Zhang, W, Yang, D, Russell, C, Spicer, D, Synold, T, Bayer, R, Hantel, A, Stiff, PJ, Tetef, ML, Gandara, DR & Albain, KS 2009, 'Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer', Journal of Clinical Oncology, vol. 27, no. 13, pp. 2163-2169. https://doi.org/10.1200/JCO.2008.17.4839
Chew, Helen K. ; Doroshow, James H. ; Frankel, Paul ; Margolin, Kim A. ; Somlo, George ; Lenz, Heinz Josef ; Gordon, Michael ; Zhang, Wu ; Yang, Dongyun ; Russell, Christy ; Spicer, Darcy ; Synold, Tim ; Bayer, Robert ; Hantel, Alexander ; Stiff, Patrick J. ; Tetef, Merry L. ; Gandara, David R. ; Albain, Kathy S. / Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. In: Journal of Clinical Oncology. 2009 ; Vol. 27, No. 13. pp. 2163-2169.
@article{e622a37871694fd3abecb5428d849e6a,
title = "Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer",
abstract = "Purpose: Cisplatin and gemcitabine have single-agent activity in metastatic breast cancer, and preclinical data support synergy of the combination. Two parallel, phase II trials were conducted to evaluate the response rate, response duration, and toxicities of the combination. Genetic polymorphisms were analyzed for correlation with outcomes. Patients and Methods: Eligible women had measurable disease and heavily or minimally pretreated metastatic breast cancer. The heavily pretreated protocol required prior anthracycline and taxane therapy; cisplatin as part of high-dose therapy was allowed. All patients received cisplatin 25 mg/m2 on days 1 through 4 and gemcitabine 1,000 mg/m2 on days 2 and 8 of a 21-day cycle with prophylactic granulocyte colony-stimulating factor in the heavily pretreated group. Sera from a subset of patients were evaluated by polymerase chain reaction restriction fragment length polymorphism for polymorphisms in 10 genes of interest. Results: Of 136 women enrolled, 74 were heavily pretreated. Both protocols accrued to their two-stage design. The response rate for both the heavily and minimally pretreated cohorts was 26{\%}, and the median durations of response were 5.3 and 5.9 months, respectively. In a multivariate analysis, hormone receptor-negative disease was associated with a higher response rate. The most common grades 3 or 4 toxicities were thrombocytopenia (71{\%}), neutropenia (66{\%}), and anemia (38{\%}). In a subset of 55 patients, the xeroderma pigmentosum group D (XPD)-751, x-ray cross-complementing group 3 (XRCC3) and cytidine deaminase polymorphisms were significantly associated with clinical outcomes. Conclusion: Combination cisplatin and gemcitabine is active in metastatic breast cancer regardless of prior therapy. Genetic polymorphisms may tailor which patients benefit from this regimen.",
author = "Chew, {Helen K.} and Doroshow, {James H.} and Paul Frankel and Margolin, {Kim A.} and George Somlo and Lenz, {Heinz Josef} and Michael Gordon and Wu Zhang and Dongyun Yang and Christy Russell and Darcy Spicer and Tim Synold and Robert Bayer and Alexander Hantel and Stiff, {Patrick J.} and Tetef, {Merry L.} and Gandara, {David R.} and Albain, {Kathy S.}",
year = "2009",
month = "5",
day = "1",
doi = "10.1200/JCO.2008.17.4839",
language = "English (US)",
volume = "27",
pages = "2163--2169",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "13",

}

TY - JOUR

T1 - Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer

AU - Chew, Helen K.

AU - Doroshow, James H.

AU - Frankel, Paul

AU - Margolin, Kim A.

AU - Somlo, George

AU - Lenz, Heinz Josef

AU - Gordon, Michael

AU - Zhang, Wu

AU - Yang, Dongyun

AU - Russell, Christy

AU - Spicer, Darcy

AU - Synold, Tim

AU - Bayer, Robert

AU - Hantel, Alexander

AU - Stiff, Patrick J.

AU - Tetef, Merry L.

AU - Gandara, David R.

AU - Albain, Kathy S.

PY - 2009/5/1

Y1 - 2009/5/1

N2 - Purpose: Cisplatin and gemcitabine have single-agent activity in metastatic breast cancer, and preclinical data support synergy of the combination. Two parallel, phase II trials were conducted to evaluate the response rate, response duration, and toxicities of the combination. Genetic polymorphisms were analyzed for correlation with outcomes. Patients and Methods: Eligible women had measurable disease and heavily or minimally pretreated metastatic breast cancer. The heavily pretreated protocol required prior anthracycline and taxane therapy; cisplatin as part of high-dose therapy was allowed. All patients received cisplatin 25 mg/m2 on days 1 through 4 and gemcitabine 1,000 mg/m2 on days 2 and 8 of a 21-day cycle with prophylactic granulocyte colony-stimulating factor in the heavily pretreated group. Sera from a subset of patients were evaluated by polymerase chain reaction restriction fragment length polymorphism for polymorphisms in 10 genes of interest. Results: Of 136 women enrolled, 74 were heavily pretreated. Both protocols accrued to their two-stage design. The response rate for both the heavily and minimally pretreated cohorts was 26%, and the median durations of response were 5.3 and 5.9 months, respectively. In a multivariate analysis, hormone receptor-negative disease was associated with a higher response rate. The most common grades 3 or 4 toxicities were thrombocytopenia (71%), neutropenia (66%), and anemia (38%). In a subset of 55 patients, the xeroderma pigmentosum group D (XPD)-751, x-ray cross-complementing group 3 (XRCC3) and cytidine deaminase polymorphisms were significantly associated with clinical outcomes. Conclusion: Combination cisplatin and gemcitabine is active in metastatic breast cancer regardless of prior therapy. Genetic polymorphisms may tailor which patients benefit from this regimen.

AB - Purpose: Cisplatin and gemcitabine have single-agent activity in metastatic breast cancer, and preclinical data support synergy of the combination. Two parallel, phase II trials were conducted to evaluate the response rate, response duration, and toxicities of the combination. Genetic polymorphisms were analyzed for correlation with outcomes. Patients and Methods: Eligible women had measurable disease and heavily or minimally pretreated metastatic breast cancer. The heavily pretreated protocol required prior anthracycline and taxane therapy; cisplatin as part of high-dose therapy was allowed. All patients received cisplatin 25 mg/m2 on days 1 through 4 and gemcitabine 1,000 mg/m2 on days 2 and 8 of a 21-day cycle with prophylactic granulocyte colony-stimulating factor in the heavily pretreated group. Sera from a subset of patients were evaluated by polymerase chain reaction restriction fragment length polymorphism for polymorphisms in 10 genes of interest. Results: Of 136 women enrolled, 74 were heavily pretreated. Both protocols accrued to their two-stage design. The response rate for both the heavily and minimally pretreated cohorts was 26%, and the median durations of response were 5.3 and 5.9 months, respectively. In a multivariate analysis, hormone receptor-negative disease was associated with a higher response rate. The most common grades 3 or 4 toxicities were thrombocytopenia (71%), neutropenia (66%), and anemia (38%). In a subset of 55 patients, the xeroderma pigmentosum group D (XPD)-751, x-ray cross-complementing group 3 (XRCC3) and cytidine deaminase polymorphisms were significantly associated with clinical outcomes. Conclusion: Combination cisplatin and gemcitabine is active in metastatic breast cancer regardless of prior therapy. Genetic polymorphisms may tailor which patients benefit from this regimen.

UR - http://www.scopus.com/inward/record.url?scp=65549094094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549094094&partnerID=8YFLogxK

U2 - 10.1200/JCO.2008.17.4839

DO - 10.1200/JCO.2008.17.4839

M3 - Article

C2 - 19307510

AN - SCOPUS:65549094094

VL - 27

SP - 2163

EP - 2169

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 13

ER -